Pilot Phase II Trial of Imatinib Mesylate in Neurofibromatosis Type 1 patients with Plexiform Neurofibromas

BACKGROUND: Plexiform neurofibromas (PN) are slow growing chemoradiotherapy resistant tumours arising in patients with neurofibromatosis type I (NF1). Currently there are no viable therapeutic options for patients whose life-threatening plexiform neurofibromas cannot be surgically removed due to pro...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Lancet Oncol
Autores principales: Robertson, Kent A., Nalepa, Grzegorz, Yang, Feng-Chun, Bowers, Daniel C., Ho, Chang Y., Hutchins, Gary D., Croop, James M., Vik, Terry A., Denne, Scott C., Parada, Luis F., Hingtgen, Cynthia M., Walsh, Laurence E., Yu, Menggang, Pradhan, Kamnesh R., Edwards-Brown, Mary K., Cohen, Mervyn D., Fletcher, James W., Travers, Jeffrey B., Staser, Karl W., Lee, Melissa W., Sherman, Marcie R., Davis, Cynthia J., Miller, Lucy C., Ingram, David A., Clapp, D. Wade
Formato: Artigo
Lenguaje:Inglês
Publicado: 2012
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5380388/
https://ncbi.nlm.nih.gov/pubmed/23099009
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(12)70414-X
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares